Table 5.

Disease-specific profiles of elevated twofold lipid elements of patients with severe acute pneumonia (SAP), acute pulmonary embolism (APE), or acute exacerbation of chronic pulmonary diseases (AECPD) with statistical significance, as compared with healthy control (p < 0.05 or less)

SAP			APE			AECPD
Elements	Folds	pvalue	Elements	Folds	pvalue	Elements	Folds	pvalue
Elevated twofold lipid elements
d181So	21.71	0.04	PC 16:0/26:0	3.98	0.02	lysoPI 22:4 (sn-1)	5.55	0.03
lysoPS17:1	8.70	0.03	lysoPS16:1	3.09	0.01	lysoPS22:6	3.28	0.05
lysoPE 22:6 (sn-1)	5.99	0.05	lysoPS17:0	3.01	0.01	lysoPC 17:1 (sn-1)	3.24	0.04
lysoPG14:0	5.90	0.01	lysoPC 22:6 (sn-1)	2.56	0.01	lysoPI 20:0 (sn-1)	2.80	0.03
lysoPS16:0	5.44	0.01	lysoPC 19:0 (sn-1)	2.50	0.01	lysoPS20:4	2.71	0.03
PS32:0	4.43	0.03	lysoPC 20:3 (sn-1)	2.48	0.02	lysoPG15:0	2.46	0.04
PS32:1	4.07	0.01	lysoPC 20:5 (sn-1)	2.40	0.01	PS37:5	2.10	0.01
lysoPI 20:2 (sn-1)	4.02	0.02	PC 39:0	2.36	0.00	PG36:2	2.08	0.01
lysoPS14:0	3.64	0.02	lysoPC 18:0 (sn-1)	2.33	0.01
lysoPI 19:0 (sn-1)	3.52	0.00	lysoPC 20:4 (sn-1)	2.31	0.01
PC 39:2	3.45	0.02	lysoPC 18:3 (sn-1)	2.30	0.03
lysoPS18:3	3.32	0.01	PS36:6	2.27	0.04
PS34:2	2.94	0.01	lysoPC 20:2 (sn-1)	2.26	0.03
PE 42:7	2.92	0.04	lysoPC 17:0 (sn-1)	2.22	0.01
PE 37:3	2.66	0.05	lysoPC 20:0 (sn-1)	2.20	0.03
PC 37:4	2.44	0.02	lysoPS20:5	2.20	0.03
PE 35:1	2.26	0.04	PS38:7	2.18	0.01
PS33:2	2.23	0.04	PC 40:7	2.17	0.00
PS35:2	2.23	0.01	lysoPC 15:0 (sn-2)	2.12	0.04
PE 39:6	2.11	0.02	lysoPC 16:0 (sn-2)	2.12	0.01
lysoPG18:3	2.08	0.04	PS33:0	2.11	0.02
PC 40:5	2.06	0.00	lysoPC 18:1 (sn-1)	2.05	0.02
PC 40:8	2.01	0.03
Declined twofold lipid elements
PA 18:1/20:4	0.25	0.04	PA 14:0/24:5	0.18	0.04	PA 10:0/18:0	0.43	0.00
PG40:5	0.47	0.03	PA 18:0/20:5	0.35	0.02	PA 10:0/18:1	0.44	0.02
PG40:6	0.33	0.00	PS38:1	0.39	0.02	PA 16:1/18:4	0.33	0.03
PG40:8	0.31	0.00	PS40:1	0.32	0.04	PS 18:0/22:3	0.46	0.01
PI 18:0/17:1	0.39	0.00				PS 20:3/22:6	0.45	0.02